|
Raludotatug deruxtecan Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: DS-6000a, MK-5909, MK-5909, R-DXd, R-DXd
Pipeline
Phase 2: 2Phase 1/2: 1
Top Sponsors
- Merck Sharp & Dohme LLC2
- Daiichi Sankyo1
Indications
- Cancer3
- Ovarian Cancer Recurrent1
- Metastatic Solid Tumors1
- Carcinoma, Non-Small-Cell Lung1
- Advanced Solid Tumor1
Marietta, Georgia1 trial
Lexington, Kentucky1 trial
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
University of Kentucky Chandler Medical Center ( Site 0019)
Phase 2
Louisville, Kentucky1 trial
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.